My LDL Looks Fine. Could ApoB Tell a Different Story?
LDL-C shows how much cholesterol is being carried. ApoB helps estimate how many atherogenic particles are carrying it. When those answers disagree, risk may look different.
Dear reader,
Here is the question that changed this Letter:
My LDL looks reasonable. Could ApoB tell a different story?
I asked Allan Sniderman, Professor of Medicine at McGill University and one of the leading investigators in ApoB science, to review the brief lipid section in HEART RESERVE. We did not begin in complete agreement. He challenged the limited role I had given ApoB. I went back to the evidence and rewrote the explanation.
That exchange is exactly what this Letter should do: show you where the science is settled, where experts and guidelines differ, and what question may make your own conversation more useful.
The short answer
Yes—sometimes knowing ApoB can change how risk is understood.
The blood test does not change your risk. It reveals information that may already be there. When ApoB and LDL cholesterol tell the same story, the result may add little. When they disagree, ApoB can uncover a higher number of plaque-forming particles than LDL-C alone suggests.
That can change a clinician's estimate of lipid-related risk, what gets followed, or how strongly prevention is discussed. It does not, by itself, diagnose plaque, prove that an artery is blocked, or decide that medication is right for you.
The heart explanation
LDL-C shows the cargo. ApoB shows the traffic.
Think of cholesterol as cargo and the particles carrying it as cars. Two women can carry a similar amount of cholesterol in very different numbers of particles. The cargo can look similar while the traffic is not.
Because each atherogenic particle carries one ApoB molecule, an ApoB measurement acts as a practical estimate of how many of those particles are circulating. More particles create more opportunities for a particle to enter the artery wall over time.
Do not blend the tests
Different question. Different answer.
LDL-C
The amount of cholesterol carried inside LDL particles.What it helps answerHow much LDL cholesterol is circulating?
What it cannot answer aloneHow many atherogenic particles are carrying that cholesterol.
ApoB
A practical estimate of the number of ApoB-containing particles.What it helps answerIs particle-related risk higher than the standard lipid panel makes it appear?
What it cannot answer aloneWhether plaque is already present or whether treatment is right for you.
Lp(a)
A specific, largely inherited particle measured with its own blood test.What it helps answerIs an inherited Lp(a)-related risk enhancer part of my story?
What it cannot answer aloneApoB does not replace Lp(a), and Lp(a) does not replace ApoB.
CAC or CCTA
Imaging that asks whether plaque is visible in the coronary arteries.What it helps answerIs there evidence of coronary plaque now?
What it cannot answer aloneWhy the plaque developed or what your particle burden has been over time.
When the extra information may matter
The mismatch is the story.
The 2026 ACC/AHA dyslipidemia guideline says ApoB can be useful after LDL-C and non-HDL-C goals are met, particularly with diabetes, triglycerides above 200 mg/dL, or a very low achieved LDL-C. Research in women has also shown that when cholesterol mass and particle number disagree, risk tends to follow particle concentration more closely.
Dr. Sniderman's evidence-based view goes further: he believes ApoB should be measured routinely because discordance cannot always be predicted in advance. That is an expert position—not the exact wording of the current U.S. guideline.
HEART RESERVE does not pretend that a live scientific debate is a settled rule. It gives you the distinction and a question you can use.
Independent expert perspective
The review made the explanation stronger.
“Lisa Zahakos reached out to me to review the brief segment of her book that deals with lipids and apoB. I did not know her and I did not agree completely with what she had initially written about apoB. But I was impressed with the rest of what she was writing and the way she is writing it. She sees cardiovascular disease as a process that occurs over time. She focuses on the period of the menopause, but this attention is situated within the continuum of the disease. She writes very well- clearly, concisely- and this reflects the fact she thinks very well.. I would have been honoured to be able to work with her.”Allan Sniderman · Professor of Medicine · McGill University
Dr. Sniderman reviewed the brief lipids and ApoB material. This statement is displayed with his written permission. It does not imply review or endorsement of the full book, website, or every HEART RESERVE recommendation.
Coming next: Lp(a)
One inherited number. A changed guideline. New trial questions.
Lp(a) is not ApoB. The 2026 guideline recommends measuring Lp(a) at least once in adulthood. New drug-trial news reported on September 4 makes the treatment story more complicated—not the reason to know whether elevated Lp(a) belongs in your history.
Full trial results are still pending. HEART RESERVE will separate what the study actually found from what headlines may imply.
From Lisa
The most useful medicine is not the longest list of tests. It is knowing which question each test answers—and what could change because you asked it.
That is the standard for every HEART RESERVE Letter: one real question, expert scrutiny when it matters, evidence you can open, and one next step you can carry into qualified care.
With care,
Lisa Zahakos, PA-CFounder, HEART RESERVEPut the number into your story
A result is a photograph. Your history is the movie.
Use the private HEART RESERVE Midlife Check to organize the numbers, history, symptoms, and unanswered questions you already have. Nothing is scored, diagnosed, submitted, or stored.
Start the private Midlife CheckEvidence behind this Letter
Sources and review
Sources last checked by Lisa for accuracy: September 5, 2026
- 2026 Guideline on the Management of DyslipidemiaACC/AHA Multisociety Guideline · Circulation · 2026
- Cost-Effectiveness of ApoB, Non–HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering TherapyJAMA · 2026
- Discordance Between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in WomenClinical Chemistry · 2017
- ApoB and Lp(a): Core Measures to Assess Cardiovascular RiskEuropean Heart Journal · 2025
- Pelacarsen Lowers Lp(a) but Lp(a) HORIZON Does Not Meet Its Primary Cardiovascular Endpoint — Top-Line ReportNovartis · full trial data pending · 2026
Independent clinical review is identified only when completed and approved in writing. No external reviewer or organization is implied. Sources do not imply endorsement of HEART RESERVE.